Tarsus Pharmaceuticals (TARS) investor relations material

Commercial performance and outlook

• XDEMVY launch for Demodex blepharitis is at an inflection point, with strong Q1 revenues of $145 million and full-year guidance of $678–$700 million reaffirmed despite seasonal headwinds and weather impacts.

• Growth is driven by increasing depth of prescribing, expanding prescriber base, and high employee engagement, with over 20,000 doctors now writing prescriptions.

• Direct-to-consumer (DTC) marketing spend remains at $80 million, with ROI improving and campaign refreshes planned to further boost awareness and impact.

• Seasonality affects quarterly cadence, with Q2 expected to see a step up in growth and Q4 typically being the strongest quarter.

• Operating leverage is increasing, with commercial investments largely stable and only variable fees scaling with volume, freeing capital for pipeline and business development.

Market opportunity and competitive landscape

• Peak U.S. sales guidance for XDEMVY has been raised to over $2 billion, supported by an expanding total addressable market (TAM) and broadening prescriber base.

• The product’s visible disease profile, ease of diagnosis, and high patient motivation differentiate it from other eye care therapies.

• Competitive threats are monitored, but XDEMVY’s efficacy, safety, and targeted mechanism are seen as high barriers for new entrants.

• Over 90% of lives are covered across commercial and Part D, with no anticipated major changes in payer coverage or significant price erosion.

• Pharmacoeconomic modeling and real-world data are used to reinforce value to payers and support pricing stability.

Pipeline development and strategic priorities

• Two phase II assets are advancing: a sterile gel for ocular rosacea (top-line data expected H1 2027) and an oral formulation for prophylactic Lyme disease (phase IIb enrolling 700 patients in one tick season).

• Ocular rosacea program leverages the same API as XDEMVY, with confidence drawn from prior positive results in papulopustular rosacea.

• The Lyme disease program demonstrated rapid and durable tick kill in a prior study, with the current trial focusing on safety, PK, and exploratory biomarkers.

• Regulatory discussions are ongoing for both programs, with potential for expedited pathways, especially for Lyme disease given public health priorities.

• Strategic focus remains on growing XDEMVY, investing in pipeline, and exploring business development to expand the eye care portfolio.